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Abstract Cadmium (Cd) is a nephrotoxic environ-
mental pollutant that causes insidious injury to the
proximal tubule that results in severe polyuria and
proteinuria. Cystatin C is a low molecular weight
protein that is being evaluated as a serum and urinary
biomarker for various types of ischemic and nephro-
toxic renal injury. The objective of the present study
was to determine if cystatin C might be a useful early
biomarker of Cd nephrotoxicity. Male Sprague–Daw-
ley rats were given daily injections of Cd for up to
12 weeks. At 3, 6, 9 and 12 weeks, urine samples were
analyzed for cystatin C, protein, creatinine, b2
microglobulin and kidney injury molecule-1. The
results showed that Cd caused a significant increase in
the urinary excretion of cystatin C that occurred
3–4 weeks before the onset of polyuria and protein-
uria. Serum levels of cystatin C were not altered by Cd.
Immunolabeling studies showed that Cd caused the
relocalization of cystatin C from the cytoplasm to the
apical surface of the epithelial cells of the proximal
tubule. The Cd-induced changes in cystatin C labelling
paralleled those of the brush border transport protein,
megalin, which has been implicated as a mediator of
cystatin C uptake in the proximal tubule. These results
indicate that Cd increases the urinary excretion of
cystatin C, and they suggest that this effect may
involve disruption of megalin-mediated uptake of
cystatin C by epithelial cells of the proximal tubule.
Keywords Cadmium  Biomarkers  Cystatin C 
Nephrotoxicity  Proximal tubule
Introduction
Cd is an important industrial and environmental
pollutant that can damage various organs including
the lung, liver, kidney and bone (ATSDR 2008; Jarup
and Akesson 2009). In addition, Cd can act as an
endocrine disruptor and it is carcinogenic (ATSDR
2008; Byrne et al. 2009; Joseph 2009). With the
chronic, low-level patterns of exposure that are
common in humans, the kidney is the primary target
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of toxicity, where Cd accumulates in the epithelial
cells of the proximal tubule, resulting in a generalized
reabsorptive dysfunction characterized by polyuria
and low molecular weight proteinuria (Jarup 2002;
Jarup and Akesson 2009; Prozialeck and Edwards
2010, 2012). In addition, some evidence suggests that
Cd-induced kidney injury can result in alterations
(either increases or decreases) in glomerular function
(Weaver et al. 2011). These effects can result from
even relatively low levels of exposure, and children
and individuals with confounding health conditions,
such as diabetes, may be especially vulnerable
(Akesson et al. 2005; ATSDR 2008; de Burbure
et al. 2006; Edwards and Prozialeck 2009; Friedman
et al. 2006; Navas-Acien et al. 2009; Trzeciakowski
et al. 2014).
As a result of its ability to accumulate Cd and its
sensitivity to injury, the kidney is, in effect, a sentinel
of Cd exposure, and much attention has been focused
on the identification of the early stages of Cd
nephrotoxicity. However, this issue has been compli-
cated by the fact that many standard metrics for
identifying kidney injury such as blood urea nitrogen
(BUN), serum creatinine and urinary protein are not
sensitive markers of Cd-induced kidney injury. Over
the years, several other urinary biomarkers have been
found to be more sensitive indicators of Cd-nephro-
toxicity. Some of the biomarkers that have proven to
be most useful include low molecular weight proteins
such as b2-microglobulin and metallothionein, and the
proximal tubule-derived enzyme N-acetyl-b-D-glu-
cosaminidase (NAG) (For reviews see, Jin et al.
1999; Kawada et al. 1995; Moriguchi et al. 2009;
Prozialeck 2013; Prozialeck and Edwards 2010,
2012). However, even though these markers have
been used to monitor Cd toxicity in humans and
experimental animals, several problems remain. For
example, these markers only identify relatively late
stages of Cd-induced injury. By the time changes in
these markers become evident, the effects of Cd on the
kidney may be severe and irreversible (Prozialeck and
Edwards 2012; Wu et al. 2011). Moreover, each of
these agents possesses some unusual properties that
complicate their use as markers of Cd nephrotoxicity.
For example, the urinary excretion of metallothionein
reflects both Cd exposure as well as proximal tubular
injury; identifying the critical level of urinary metal-
lothionein to indicate the onset of tubular injury has
been problematic (Prozialeck 2013; Prozialeck and
Edwards 2010). With regard to b2-microglobulin, it is
not totally clear if increases in its urinary excretion are
solely the result of proximal tubule dysfunction or may
also reflect plasma levels of the protein, which can be
influenced by actions of Cd at the glomerulus or on
organs other than the kidney. A major problem with
NAG is that enzyme activity can be affected by other
substances, particularly toxic metals such as Hg, that
might also be present in urine of metal-exposed
subjects (Prozialeck 2013; Prozialeck and Edwards
2010). As a result of these problems, there is a need for
more sensitive markers of Cd nephrotoxicity. One
molecule that shows significant potential in this
context is cystatin C.
Cystatin C is a 13 kDa cysteine protease inhibitor
that is produced by cells throughout the body. Cystatin
C is abundant in serum/plasma and is readily filtered at
the glomerulus. Serum levels of cystatin C have been
proposed as a useful marker to estimate glomerular
filtration rate (Filler et al. 2005; Ghys et al. 2014; Parikh
et al. 2010; Parikh and Devarajan 2008; Peralta et al.
2011; Vaidya et al. 2008). Unlike creatinine, cystatin C
is not secreted by the proximal tubule. Instead, filtered
cystatin C is taken up through a megalin-dependent
process and then completely catabolized in proximal
tubule epithelial cells (Ghys et al. 2014). Serum levels
of cystatin C are much less likely to be affected by
factors such as gender, metabolic status or disease states
than are levels of creatinine (Ghys et al. 2014; Ozer et al.
2010; Parikh et al. 2010, 2011; Parikh and Devarajan
2008; Vaidya et al. 2008).
Changes in both serum and urinary levels of
cystatin C have been observed in various models of
kidney injury (Dieterle et al. 2010; Ghys et al. 2014;
Parikh et al. 2010; Vaidya et al. 2008; Zhang et al.
2011). Several equations for estimating glomerular
filtration based on serum levels of cystatin C have been
developed, and there is evidence that these cystatin
C-based measurements may out-perform traditional
creatinine-based estimates of GFR (Ghys et al. 2014;
Inker and Okparavero 2011; Stevens et al. 2010;
Weinert et al. 2011; Zhang et al. 2011). However,
there is also some evidence that proteinuria and
proximal tubular damage may influence the urinary
excretion of cystatin C and affect cystatin C-based
estimates of renal function (Dieterle et al. 2010; Kim
et al. 2012).
Cystatin C has recently received some attention as a
potential biomarker of Cd nephrotoxicity (Harisa et al.
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2014; Poreba et al. 2011; Shelley et al. 2012; Wallin
et al. 2014; Weaver et al. 2011, 2014; Wu et al. 2011).
However, those studies focused primarily on the
measurement of serum levels of cystatin C as an
indicator of glomerular function and they yielded
equivocal and somewhat conflicting results. Most of
the studies did not include data on the possible effects
of Cd on the urinary excretion of cystatin C. In our
own preliminary studies utilizing a subchronic model
of Cd exposure in rats, we found significant increases
in urinary cystatin-C that occurred with even relatively
short-term Cd exposure (VanDreel et al. 2012). In
addition, Immunolabeling studies revealed significant
alterations in the patterns of cystatin-C localization in
the proximal tubule epithelium. In light of these
preliminary findings, additional studies on the effects
of Cd on serum and urinary levels of cystatin C seemed
warranted.
The present studies were aimed at further charac-
terizing the possible utility of cystatin C as an early
urinary and/or serum biomarker of Cd nephrotoxicity.
In addition, we examined the effects of Cd on the
localization of cystatin C in the kidney. These studies
involved the use of a well-established model of long-
term Cd-exposure in the rat and the direct comparison
of the cystatin C results with those of a panel of
standard markers of Cd toxicity and kidney function
(b2 microglobulin, Kim-1, total protein and
creatinine).
Materials and methods
Animal work was conducted in compliance with the
United States NIH Guide for the Care and Use of
Laboratory Animals (National Research Council of
the National Academies 2011), and the studies were
approved by the Institutional Animal Care and Use
Committee of Midwestern University. Adult male
Sprague–Dawley rats weighing 250–300 g (Harlan,
Indianapolis, IN) were housed socially (two rats per
plastic cage) on a 12 h/12 h light/dark cycle. For the
low-dose, chronic studies, animals in the Cd treatment
group (n = 6) received daily (Monday–Friday) sub-
cutaneous injections of CdCl2 at a Cd dose of 0.6 mg
(5.36 lmol)/kg in 0.25–0.35 ml isotonic saline for up
to 12 weeks. Control group animals (n = 6) received
daily injections of the saline vehicle alone. After 3, 6, 9
and 12 weeks of treatment, the animals were placed in
individual metabolic cages and 24 h urine samples
were collected. The animals were allowed free access
to water at all times. Food was also available
ad libitum, except during the period in which the
urine samples were being collected. The 12 week Cd
treatment protocol was repeated twice and data from
the two treatment protocols were pooled whenever
possible. In another study, groups of animals were
treated with varying doses of Cd (0, 0.6 or 1.2, or
2.4 mg/kg) 5 days per week for 1–3 weeks. Before the
start of each experiment, the Cd concentrations of all
stock solutions used for the various treatment proto-
cols were verified by Chemical Solutions, Inc. using
the technique of inductively coupled plasma mass
spectroscopy.
Urine and blood analysis
After collection, the 24-h urine samples were
aliquoted into 0.5–1.0 ml portions. The aliquots were
frozen at -80 C and later assayed for protein,
creatinine, and the biomarkers of interest. In some
cases, prior to freezing, the urine aliquots were
stabilized in proprietary buffers and other reagents
that are recommended for MAGPIX-based assays that
were used for some of the analyses. Blood samples
were obtained at the time the animals were euthanized
and serum levels of cystatin C was determined by an
enzyme-linked immunoabsorbent assay (ELISA)
(R?D Systems) according to the manufacturer’s
protocol.
Biomarker determination
The urinary levels of cystatin C, Kim-1 and b2-
microglobulin, were determined by microsphere-
based Luminex x MAP technology using the MagPix
xPONENT 4.1 equipment. The Multiplex technology
allows for the determination of multiple analyses in a
single sample and provides much greater sensitivities
and dynamic ranges than commonly-used ELISA’s.
This technique is similar to the assay that has been
used to determine urinary levels of Kim-1 in our
previous studies (Prozialeck et al. 2007, 2009a, b).
Urinary levels of creatinine were determined by the
colorimetric method of Shoucri and Pouliot (1977).
With the dosing protocol used in these studies, Cd-
treated animals tended to gain less weight than control
animals (Prozialeck et al. 2007). Accordingly, all
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urinary parameters were expressed as units excreted
per kg body weight per 24 h.
Visualization of cystatin C and megalin
In our initial studies, cystatin C and megalin in
individual tissue sections were visualized by separate
immunohistochemical labeling procedures. Formalin-
fixed, paraffin-embedded tissue sections (5 lm) were
deparaffinized in xylene, rehydrated with a series of
alcohol washes, and then incubated for 20 min at
95 C in a citrate buffer solution (Vector Laboratories,
#H3300). The sections were quenched for endogenous
peroxidase by incubation in 0.3 % hydrogen peroxide
in methanol at -20 C. After quenching, the sections
were blocked at room temp for 15 min in undiluted
Background Reducing Buffer (Abcam, # ab64234).
The samples were then incubated overnight at 4 C in
the primary antibodies, either a 1:100 dilution of goat
anti-cystatin C (Abcam, # ab117642) or a 1:100
dilution of rabbit anti-megalin (Abcam, cat #
ab76969).The primary antibodies were visualized
using the avidin–biotin horseradish peroxidase tech-
nique according to the manufacturer’s protocol (Vec-
tor Laboratories, Vectastain Elite ABC Kit PK 6104 or
PK6102). The samples were then counterstained with
hematoxylin. Negative controls consisted of tissue
sections that were incubated without the primary
antibody.
In other experiments, a dual-labeling indirect
confocal immunofluorescence procedure was used to
visualize cystatin C and megalin in the same tissue
sections. Fresh cryosections of rat kidney (5–20 lm)
were fixed and permeabilized for 10 min in -20 C
methanol and then incubated for 15 min in undiluted
Background Reducing Buffer (Abcam, # ab64234).
The samples were then incubated overnight at 4 C in
the primary antibodies at a 1:100 dilution of goat anti-
cystatin C (Abcam, # ab117642) or a 1:100 dilution of
rabbit anti-megalin (Abcam, cat # ab76969). The
samples were washed in PBS and incubated for 40 min
in the secondary antibodies at a 1:200 dilution of
TRITC conjugated chicken anti-rabbit IgG (Abcam, #
ab6826) and a 1:100 dilution of Alexa Fluor488-
conjugated donkey anti-goat IgG (Abcam, #
ab150129). Samples were then washed in deionized
water, mounted and viewed. Controls consisted of
samples that were incubated without the primary
antibodies.
For most of the studies, samples were viewed with a
Nikon Eclipse E-400 microscope using a 940 objec-
tive. Images were captured with a digital camera
(Media Cybernetics) using automated exposure times
and gain settings. The digital images were processed
using the Image-Pro Plus image analysis software
package (Media Cybernetics). To further characterize
the patterns of cystatin C and megalin labeling in
specific nephron segments, some of the samples were
also examined using a Nikon Eclipse Ti microscope
fitted with a Nikon A1R confocal interface with Nikon
Elements C software on a HPZ400 computer. A stack
of up to 100 images per section was acquired in 0.05
micron increments under a 960 oil objective and
representative images were selected from each stack.
Negative controls for all labeling studies consisted
of kidney sections that were incubated without the
primary antibodies, as well as sections that were
incubated with non-diluted, non-immune serum from
the same species in which the primary antibodies had
been generated. To rule out the possibility that any
apparent labeling may have resulted from fluorescence
‘‘spill over’’ when the FITC labeled samples were
viewed with the TRITC filter configuration and vice
versa, all experiments also included a group of
samples that were labeled with each of the TRITC-
or FITC-tagged antibodies individually. When the
TRITC-labeled samples were viewed with the FITC
filter configuration and the FITC-labeled samples were
viewed with the TRITC filters, no labeling was evident
in any of the samples. All labeling experiments were
repeated at least three times and appeared to be highly
reproducible.
Image analyses
For the immunohistochemistry images in Fig. 5, the
Image J computer program was used to create hand
drawn regions of interest around each proximal tubule
using the hematoxylin staining as a morphological and
structural guide. Thresholds were set at (X-115) to
identify pixels that were brown and above average
background noise due to positively stained peroxidase
signals from cystatin C and megalin. Total brown
pixels for cross sections of each tubule were measured.
A second region of interest was hand drawn within
each tubule to capture 1–2 cells at the border of the
cytoplasm and the cystatin C and megalin pixels above
background. The percentages of apical/luminal
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cystatin C and megalin pixels were then calculated
from the total pixels/tubule.
Fluorescence co-localization of cystatin C and
megalin images in Fig. 6 was also measured using
the Image J program. Megalin (red) and cystatin C
(green) images were split into their separate channels.
The average backgrounds were used to set thresholds
for the red (25–255) and green (30–255) channels. The
Coloc 2 plug-in was then used to determine the
Pearson’s correlation and Manders split coefficients of




Statistical analyses were done using the GraphPad
Prism Computer Program. Data for the various serum
and urinary parameters were evaluated by two differ-
ent types of analyses. The first approach involved the
use of standard two-way ANOVA, followed by post
hoc Tukey’s tests to determine the differences among
the various treatment groups, whenever the p value for
the ANOVA was less than 0.05. This was done
because similar tests have been commonly used in
many of the previous studies on the urinary excretion
of these markers in similar animal models (Arsalane
et al. 1999; Bernard and Hermans 1997; Lee et al.
1983; Lermioglu and Bernard 1998; Sugihira et al.
1986). However, while performing these analyses, we
found that this approach might not be appropriate
because the data points for the later treatment periods
showed significantly more variability than the points
for the earlier treatment periods. ANOVA and Tukey’s
tests are parametric tests that assume normality of
distribution and homogeneity of variances (i.e. that
SD’s are equal for all treatment groups) (Zar 1996).
Analysis of the present data by the Kolmogorov–
Smirnov test (normality) and Levene’s test (homo-
geneity of variances) showed that much of the data did
not meet these criteria. Accordingly, the data were also
analyzed by the non-parametric Kruskal–Wallis test
and Dunn’s post hoc test for multiple comparisons,
which are more appropriate for these types of variable,
heterogeneous data (Zar 1996). Since many previous
studies on these markers utilized parametric methods,
we have included the results of both our parametric
and non-parametric analysis so that the reader can
directly compare the results of this study with those
previously reported in the literature.
Results
Figure 1 shows the effects of Cd (0.6 mg/kg, 5 days
per week) on urine volume (a) and the urinary
excretion of protein (b), creatinine (c) and a panel of
biomarkers including cystatin C (d), b2 microglobulin
(e) and Kim-1 (f). As may be seen, treatment with Cd,
increased urine volume (graph a) and total urinary
protein excretion (graph b). These changes reached
levels of statistical significance after about 9 weeks of
Cd exposure. Cd had no significant effect on the
urinary excretion of creatinine even after 12 weeks
(graph c). The development of polyuria and protein-
uria, with no change in creatinine excretion is
characteristic of Cd-induced proximal tubule dysfunc-
tion (Prozialeck et al. 2007). The urinary excretion of
cystatin C was significantly elevated at 3–6 weeks,
depending on the statistical method that was used and
continued to increase throughout the remainder of the
12 week treatment protocol (graph d). With the
parametric statistical tests (2 way-ANOVA and
Tukey’s post hoc test), urinary cystatin C levels were
significantly elevated after only 3 weeks. However, as
noted in ‘‘Materials and methods’’ section, such
parametric tests are not totally appropriate for this
type of data where variances are not homogeneous.
When the more appropriate non-parametric Kruskal–
Wallis and Dunn’s post hoc tests were used, the levels
of cystatin C were significantly elevated after 6 weeks
of exposure. The time course for the increase in
cystatin C excretion was similar to that of the classic
Cd biomarkers b2 microglobulin (graph e) and the
more-recently described marker Kim-1 (graph f). It
should be noted that in the present study, even though
Kim-1 appeared to be slightly increased after as little
as 6 weeks into the treatment protocol, the increase
did not reach a level of statistical significance until
9 weeks. Our previous studies with Kim-1 using this
same model showed significant increases in urinary
Kim-1 after only 6 weeks. We cannot explain the
reason for this slight discrepancy. However, it is
interesting to note that when the Kim-1 data from
weeks 3 and 6 of the present study were analyzed
without inclusion of the 9 and 12 week data, the
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increase in Kim-1 was statistically significant
(p\ 0.05) at 6 weeks. This illustrates the fact that as
the variance of the biomarker data increases with
longer exposure times, the statistical significance of
changes that might be evident at earlier time points can
be obscured. In this context, the significance of results
of a particular biomarker at any given time point is to a
certain extent dependent on the duration of exposure in
the overall study.
Nevertheless, the salient point from this data as a
whole is that cystatin C appears to be a very early
urinary marker of the Cd toxicity. It should also be
noted that our observed values for cystatin C, Kim-1
and b2 microglobulin were also within reference
ranges provided by the manufacturer of the reagents
(Millipore Inc.). Moreover, similar values for urinary
cystatin C, b2 microglobulin and Kim-1 have been
reported by other investigators (Cardenas-Gonzalez
et al. 2013; Dieterle et al. 2010; Gautier et al. 2014a, b;
Ghys et al. 2014; John-Baptiste et al. 2012; Spanu
et al. 2014; Zhou et al. 2008).
The results of the foregoing analyses showed that
Cd caused significant increases in the urinary excre-
tion of cystatin C as early as 3–6 weeks into the
treatment period, which is 3–6 weeks before the onset
of overt signs of Cd nephrotoxicity such as polyuria
and proteinuria. The increased excretion of cystatin C
occurred in the same general time frame as the
increase in urinary excretion of b2 microglobulin and
Kim-1 which have both been used as sensitive urinary
Fig. 1 Effects of Cd on urine volume, urinary creatinine,
protein, cystatin C, b2 microglobulin and Kim-1. Male Sprague–
Dawley rats received daily subcutaneous injections of Cd
(0.6 mg/kg) for up to 12 weeks, and 1 day at weeks 3, 6, 9 and
12, 24 h urine samples were collected and analyzed for
creatinine, protein and the various biomarkers as described
under ‘‘Materials and methods’’ section. An asterisk indicates
significant differences from week matched control values as
determined by 2-way ANOVA (p\ 0.05) and Tukey’s post hoc
test. A # indicates significant differences from week matched
control values as determined by the non-parametric Kruskal–
Wallis test (p\ 0.05) and Dunn’s test for multiple comparisons.
Values represent the mean ± SEM; n = 11–24 for each data
point
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markers of Cd nephrotoxicity (Prozialeck et al. 2007;
Prozialeck 2013; Prozialeck and Edwards 2010;
Ruangyuttikarn et al. 2013).
As may be seen in Fig. 2, Cd had no effect on serum
levels of cystatin C, which are thought to reflect
glomerular filtration rate. As we have shown in our
previous studies using this same treatment protocol,
Cd also has no effect on serum levels of creatinine,
which is a classical marker of glomerular function
(Prozialeck et al. 2007, 2009a, b).
Figure 3 shows hematoxylin and eosin-stained
tissue sections of outer renal cortex from control and
Cd-treated animals. Note that proximal tubule epithe-
lial cells in the control samples (top left) exhibited
cuboidal shapes, well-defined nuclei, and a uniform
cytoplasm, with no spaces or gaps between the cells
(see arrows). By contrast, the epithelial cells in the
samples from Cd-treated animals (top right and
bottom row) showed a ragged, irregular appearance,
with gaps between the cells (see arrows). The cells
remained attached to the basement membrane, how-
ever, and showed little overt evidence of necrosis.
Analyses of the glomeruli and distal segments of the
nephron revealed no evidence of pathology. Together,
these observations along with the urinary and sero-
logical results described above are consistent with
previous findings that in this particular animal model
Cd primarily damages the proximal tubule while
having little effect on glomerular structure or function
(Prozialeck et al. 2007, 2009a, b).
To determine if the Cd-induced increase in urinary
excretion of cystatin C was dependent on the dose of
Cd, groups of rats were treated with either 0, 0.6, 1.2,
or 2.4 mg/kg Cd, 5 days per week for 1–3 weeks.
During the course of these studies, we found that
animals receiving the highest dose of Cd (2.4 mg/kg)
began to lose weight early in the treatment protocol.
Accordingly, their treatment was terminated after only
1 week. Results of the complete study are shown in
Fig. 4. After 3 weeks of treatment, the middle dose of
Cd (1.2 mg/kg) caused significant increase in the
excretion of cystatin C (graph a). The magnitude of the
increase was directly related to the dose of Cd to which
the animals treated. These patterns of cystatin C
excretion were almost identical to those observed with
Kim-1 as a marker (graph b). These results are quite
similar to those observed in our previous studies on the
identification of Kim-1 as an early biomarker of Cd
nephrotoxicity (Prozialeck et al. 2007, 2009a, b).
In order to evaluate the possible functional signif-
icance of the Cd-induced increase in urinary cystatin C
excretion, we utilized an immunohistochemical pro-
cedure to examine the effects of Cd on the localization
of cystatin C in kidney tissue sections. As may be seen
in the control sections shown in Fig. 5 (top left), fine,
well-defined bands of cystatin C labeling are present
just below the apical (brush border) of the proximal
tubule epithelial cells (see arrow). There is also
speckled, granular pattern of labeling in the cytoplasm
of most cells. Cd caused pronounced changes in these
patterns of labeling. In samples from Cd-treated
animals, cystatin C labeling was shifted to the surface
of the proximal tubule cells, making it appear as if
cystatin C is actually leaking from the cells into the
tubular lumen (see arrows).
In examining these images, we noticed that the
general pattern of cystatin C labeling was similar, in
many respects, to previously-published images show-
ing the localization of the proximal tubular transport
protein megalin (Christensen et al. 2009; Kaseda et al.
2007). Megalin is normally present on the luminal
brush border surface and in the cytoplasm of proximal
tubule epithelial cells where it plays a key role in
mediating the uptake of low molecular weight proteins
by the proximal tubule (Christensen et al. 2009;
Kaseda et al. 2007; Klassen et al. 2004; Wolff et al.
2006). It has been suggested that megalin may actually
Fig. 2 Lack of effects of Cd on serum cystatin C. Animals
received daily subcutaneous injections of Cd (0.6 mg/kg) as
described in ‘‘Materials and methods’’ section. Animals were
euthanized at 6, 9 and 12 weeks and serum was collected and
analyzed for cystatin C as described in ‘‘Materials and methods’’
section. The values represent the mean ± SEM; n = 6–11 for
each data point
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mediate the uptake of cystatin C in the proximal tubule
(Kaseda et al. 2007). Accordingly, we conducted a
series of studies examining the effects of Cd on the
localization of megalin. The results are shown in the
images at the bottom of Fig. 5. As may be seen, the
pattern of megalin distribution is similar, but not
Fig. 3 Effects of Cd on general morphology of the renal cortex.
Rats were treated with Cd (0.6 mg/kg/day) for 6, 9 or 12 weeks
as described in ‘‘Materials and methods’’ section and
representative 5 lm thick sections of the renal cortex processed
for H?E staining. The scale bar in the top right figure represents
100 lm
Fig. 4 Dose-dependence of the Cd-induced increase in cystatin
C and Kim-1 excretion. Animals were treated with varying
doses of Cd (0, 0.6, 1.2 or 2.4 mg/kg/5 days per week for
4 weeks) and urine was analyzed for levels of cystatin C and
Kim-1 as described in ‘‘Materials and methods’’ section. An
asterisks indicates significant differences from week-matched
control values as determined by 2-way ANOVA (p\ 0.05) and
Tukey’s post hoc test. A # indicates significant differences from
week matched control values as determined by the non-
parametric Kruskal–Wallis test (p\ 0.05) and Dunn’s test for
multiple comparisons. Values represent the mean ± SEM;
n = 6 for each data point
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identical to that of cystatin C. In control samples
(bottom left), megalin is mainly localized as a well-
defined band of labeling along the apical surface of the
proximal tubule epithelial cells although a significant
amount of speckled-like labeling is present in the
cytoplasm (see arrows). Interestingly Cd caused the
narrowing of this band of labeling and the apparent
movement of megalin from the cytoplasm to the
surface of the proximal tubules (see arrows).
To quantify the apparent movement of cystatin C
and megalin from the cytoplasm to the cell surface, we
utilized the Image J computer program to determine
the total number of peroxidase labeled pixels in cross
sections of the proximal tubules shown in Fig. 5, and
then calculated the percent of pixels that were located
on the brush border and the tubular lumen. Results of
these analyses are summarized in Table 1. As may be
seen, the results clearly show that Cd caused a time-
dependent shift in the localization of both cystatin C
and megalin from the cytoplasm to the apical cell
surface. The percentage of cystatin C associated with
the apical cell surface increased from less than 15 % in
the control samples to over 80 % after 12 weeks of Cd
exposure.
One interesting aspect of the data in Table 1 is that
the total cystatin C labeled pixels in the proximal
tubules appears to increase with Cd treatment. This is
somewhat surprising in that Cd is actually increasing
the urinary excretion of cystatin C. Intuitively, it
would seem that cellular levels of cystatin C should
actually decrease. While we cannot explain this
apparent paradox, we are postulating that it may
reflect inhibitory effects of Cd on the catabolism of
cystatin C within the proximal tubule cells, although
further studies are needed to clarify this issue. It is also
noteworthy that the pixel intensities for megalin show
that Cd had no consistent effects on the overall
intensity of megalin labeling, even though it did
increase the percentage of megalin on the apical cell
surface.
To further examine the possible association
between the effects of Cd on cystatin C and megalin,
we developed a dual immunofluorescence and confo-
cal procedure for the visualization of both molecules
in the same tissue cryosections. As may be seen in
Fig. 6, the patterns of labeling for both cystatin C and
megalin with this dual fluorescence method are similar
to those observed with the individual immunoperox-
idase labeling studies described in Fig. 5. In control
samples, cystatin C showed a fine band of labeling just
below the apical cell surface and a speckled, granular
pattern of labeling in the cytoplasm, whereas megalin
showed a well- defined band of labeling along the
apical cell surface as well as speckled labeling in the
cytoplasm. It should be noted that overlaid images of
both molecules together showed that even though the
two molecules showed similar patterns of labeling,
they were not exactly co-localized. This is evident in
Fig. 5 Effects of Cd on the localization of cystatin C and
megalin in the proximal tubule. Animals were treated with Cd
(0.6 mg/kg/day for up to 12 weeks) and formalin-fixed samples
of renal cortex were processed for the immunohistochemical
visualization of cystatin C and megalin as described in
‘‘Materials and methods’’ section. The samples were viewed
using a 940 objective. The scale bar in the top left photo
represents 100 lm
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the control samples that show mainly distinct regions
of red megalin labeling and green cystatin C labeling
with only isolated areas of yellow labeling where both
molecules appear to be co-localized. By contrast, in
the Cd treated samples, there appeared to be a
movement of both molecules toward the apical cell
surface. Overlaid images of both molecules showed
Cd-dependent increase in the appearance of yellow
labeling indicating an increase in the co-localization of
both molecules as they relocalized to the cell surface
and the tubular lumen.
In order to quantify the apparent Cd-induced
increase in the co-localization of cystatin C and
megalin, we utilized the Image J program to examine
the correlation between the locations of the molecules.
After background subtraction, the localization of
megalin and cystatin C in the control samples had a
Pearson’s correlation coefficient of 0.54 and a Man-
ders co-localization coefficient of 0.87 (correlation of
megalin pixels that reside in the same location as
cystatin C pixels). Over time, however, Cd exposure
altered the localization patterns of cystatin C and it co-
localized more strongly with megalin. For 9 weeks
and 12 weeks of Cd exposure, the Pearson’s correla-
tion coefficients between cystatin C and megalin were
0.70 and 0.78, and the Manders co-localization
coefficients were 0.95 and 0.91, respectively. It should
be noted that these particular images could not be used
for more sophisticated statistical analyses because the
fluorescence data in each image is essentially treated
as n = 1. This is in contrast to the immunoperoxidase
images shown in Fig. 5 in which each tubule can be
treated as n = 1. Nevertheless, the results of the
fluorescence analyses clearly indicate an increase in
the co-localization of cystatin C and megalin in the
samples from the Cd-treated animals. In addition it is
worth noting that the total pixel intensity for the
fluorescent megalin images did not appear to change
with Cd exposure, whereas the intensity of the cystatin
C labeling increased steadily over the 12 week Cd
treatment protocol. Even though no statistical analyses
could be performed on this data, the results are in
agreement with the quantitative immunoperoxidase
data summarized in Table 1.
Discussion
Cystatin C is an emerging marker of both ischemic and
nephrotoxic kidney injury (Ghys et al. 2014). Serum
Table 1 Effects of Cd on the localization of cystatin C and megalin in the proximal tubule
Sample Total labeled pixels/tubule Total labeled pixels
on apical surface
Percent of labeled pixels
on apical surface
Cystatin C
Control 94,767 ± 9490 12,515 ± 3026 12.1 ± 2.1
Cd 6 weeks 72,159 ± 5954 26,355 ± 3960 35.7 ± 4.1*
Cd 9 weeks 127,880 ± 27,992 107,114 ± 23,663 76.1 ± 2.2*
Cd 12 weeks 153,179 ± 12,307 136,144 ± 10,923 89.0 ± 2.0*
Megalin
Control 166,802 ± 25,904 45,788 ± 6808 30.3 ± 3.1
Cd 6 weeks 115,589 ± 15,109 48,167 ± 6565 41.2 ± 1.0*
Cd 9 weeks 98,532 ± 13,923 51,438 ± 6580 52.9 ± 1.8*
Cd 12 weeks 124,177 ± 9758 83,655 ± 7.384 67.1 ± 1.8*
The localization of cystatin C and megalin in the peroxidase-labeled kidney sections from Fig. 5 were quantified using the Image J
computer program. Using the hematoxylin staining as a morphologic guide, regions of interest were created around each tubule. The
number of pixels that were positive for cystatin C or megalin staining was measured using constant thresholding tools (as described in
‘‘Materials and methods’’ section) to identify peroxidase signal above background levels for each tubule. A second region of interest
(apical compartment) for each tubule was created to encompass the luminal space and 1–2 cells of the apical luminal surface. Positive
cystatin C and megalin pixels were again measured in the apical compartment using the same thresholding parameters. The percentile
data of pixels in the apical compartment was calculated and the data were evaluated by a one-way ANOVA with post hoc Tukey’s
test. Values represent the mean ± SEM of data from 7 to 10 tubules per image. An asterisks denotes that the percent of pixels in the
apical compartment is significantly greater (p\ 0.05) than in the control samples
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levels of cystatin C have been proposed as an
alternative to traditional markers such as BUN and
creatinine for the estimation of glomerular filtration
rate (Ghys et al. 2014). At the same time, increases in
the urinary excretion of cystatin C have been proposed
as a sensitive indicator of proximal tubular injury
(Ghys et al. 2014; Togashi et al. 2013; Wallin et al.
2014). The fact that cystatin C is rapidly being
accepted as a measure of renal function in the clinic
makes it extremely important to understand the effects
that specific nephrotoxic agents, such as Cd, have on
serum and urinary levels of cystatin C. While several
recent studies have addressed the possible utility of
cystatin C, a potential marker of Cd nephrotoxicity in
Cd-exposed human subjects, the studies have primar-
ily focused on measurement of serum levels of cystatin
C and have yielded conflicting results (Harisa et al.
2014; Kim et al. 2012; Poreba et al. 2011; Shelley et al.
2012; Wallin et al. 2014; Weaver et al. 2011; Wu et al.
2011). The results of the present studies utilizing a
well-established model of sub-chronic Cd exposure in
rats indicate that an increase in the urinary excretion of
cystatin C is a very early and sensitive marker of Cd-
induced proximal tubular injury. Significantly ele-
vated levels of cystatin C appeared in the urine after
3–6 weeks of treatment with Cd, whereas overt
polyuria and proteinuria, which are classic signs of
Cd-induced proximal tubule injury, did not become
Fig. 6 Effects of Cd on dual labeling of cystatin C and megalin
in renal cortex. Animals were treated with Cd (0.6 mg/kg) for 6,
9 or 12 weeks. Cryosections of renal cortex were processed for
the dual labeling and confocal imaging of cystatin C and
megalin as described in ‘‘Materials and methods’’ section. In
these images, cystatin C (top row of images) shows as green
fluorescence, whereas megalin (middle row of images) is visible
as red fluorescence. The bottom row of images show overlays of
the cystatin C and megalin images from the same tissue sections.
The samples were viewed using a 960 objective. The scale bar
on the bottom left image represents 50 lm
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evident until 9–12 weeks of Cd treatment. Dose–
response studies showed that the magnitude of the
increase in the urinary excretion of cystatin C was
directly related to the dose of Cd to which the animals
were exposed.
In order to determine whether the effects of Cd on
cystatin C may have involved alterations in glomerular
function, serum levels of cystatin C were measured.
As noted previously, cystatin C in the serum is
normally filtered at the glomerulus and then taken up
by the proximal tubule. In theory, alterations in
glomerular filtration of cystatin C could lead to
changes in serum levels of cystatin C. It should be
noted that the serum levels of cystatin C reported here
are consistent with other studies reported in the
literature (Dieterle et al. 2010; Ghys et al. 2014;
Togashi et al. 2013). We found that Cd had no effect
on serum cystatin C, which indicated that cystatin C
was being filtered normally by the kidney, and that the
increase in urinary cystatin C was most likely due to a
reduction in the reabsorptive capacity or alterations in
the catabolism of cystatin C in the proximal tubule.
Furthermore, H&E stained tissue sections (Fig. 3)
showed no evidence of changes in the structure of the
glomeruli. Together, these results strongly indicate
that the primary site of Cd-induced kidney injury in
this model is in the proximal tubule.
In assessing the utility of various biomarkers of Cd
nephrotoxicity such as cystatin C, b2 microglobulin
and Kim-1, it is important to note that each of these
molecules is derived from different sources and their
appearance in the urine is indicative of different events
in the pathophysiology of kidney injury (Prozialeck
and Edwards 2010, 2012; Thevenod and Lee 2015).
The classic view is that with chronic exposure, the
levels of Cd in the proximal tubule cells continue to
accumulate until a critical threshold concentration of
about 150–200 lg/g of tissue is reached (Jarup 2002;
Roels et al. 1979). At this point, cell function becomes
compromised and the injury can trigger autophagy and
either necrotic or apoptotic cell death (Prozialeck and
Edwards 2012; Shaikh et al. 1999; Thevenod and Lee
2015). Along with causing alterations in proximal
tubule function, cell injury leads to the shedding of
injured cells and their cytosolic contents into the urine.
The shedding of dead or injured cells triggers a repair
process in which neighboring non-injured cells ded-
ifferentiate, migrate to the denuded area of the
basement membrane and proliferate to replace the
injured cells (Prozialeck and Edwards 2012; Thevenod
and Lee 2015).
With respect to biomarkers, Kim-1 is mainly
expressed as part of the tissue repair process when
injured cells slough off from the proximal tubule and
surviving cells migrate to the denuded areas of the
basement membrane to reform the epithelial barrier
(Bailly et al. 2002; Ichimura et al. 2008). By contrast,
increases in the urinary excretion of classic low
molecular weight protein markers derived from serum
such as b2 microglobulin and cystatin C are thought to
directly reflect the reabsorptive dysfunction that
results from Cd-induced injury to the proximal tubular
epithelial cells. In light of the fact that the proximal
tubule transport protein megalin has been implicated
in these reabsorptive processes (Christensen et al.
2009; Kaseda et al. 2007; Klassen et al. 2004; Wolff
et al. 2006), we examined the possible relationship
between changes in the localization of cystatin C and
megalin in the proximal tubule. Results of direct
labeling studies clearly showed that Cd caused the
relocalization of megalin and cystatin C from the
cytoplasm to the apical surface of the epithelial cells of
the proximal tubule. Interestingly, preliminary analy-
sis of pixel intensity for megalin labeling showed no
difference between tissue samples from control and
Cd-treated animals even though in vitro studies have
suggested that Cd can reduce transcription levels of
megalin (Gena et al. 2010). At present, the mechanism
by which Cd affects the localization of cystatin C in
the proximal tubule remains unclear. However, the
present findings do suggest an association with
alterations in megalin distribution and/or function.
It should be noted that while the present discussion
focusses on the possible role of megalin in the uptake
of cystatin C, there is evidence to suggest that megalin
is also involved in the uptake of other Cd biomarkers
such as b2-microglobulin and metallothionein. This
raises the intriguing possibility that Cd might affect
the renal excretion of all of these markers by
disrupting megalin-mediated transport. Results of the
present studies showing that the time courses for the
urinary appearance of cystatin C and b2-microglobulin
are very similar indicate that they may in fact involve a
common mechanism. However, previous studies from
our laboratory (Prozialeck et al. 2007, 2009b) showed
that metallothionein, which is another substrate for
megalin transport (Klassen et al. 2004), typically does
not appear in the urine until about 6–9 weeks of
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exposure, about 3 weeks after cystatin C and b2-
microglobulin. We are postulating that such differ-
ences in the time course for the appearance of megalin
substrates in the urine could be related to differences in
the actual levels of the marker molecules, the kinetics
of their transport by megalin and/or their handling by
the epithelial cells of the proximal tubule. It is
noteworthy that Thevenod and Wolff (2015) have
recently presented evidence that metallothionein is not
endocytosed in the proximal tubule via megalin
because the concentration of metallothionein in the
primary filtrate is too low to be able to bind megalin.
These authors propose that metallothionein may rather
be endocytosed by a high- affinity receptor in the distal
nephron. Our previous work demonstrating that met-
allothionein is detected in the urine several weeks after
cystatin C and b2-microglobulin (Prozialeck et al.
2007) could suggest that this delay of urinary metal-
lothionein excretion could either reflect altered reab-
sorption of metallothionein in the distal nephron or the
release of cytosolic metallothionein from damaged
proximal tubule cells into the urine. Further studies are
needed to clarify these issues and to determine how the
findings by Thevenod and Wolff relate to our findings
on the urinary excretion of cystatin C.
In addition, there are several other caveats that need
be considered. First, the present studies merely show
an association between changes in cystatin C and
megalin localization. They do not prove any cause-
effect relationships. Secondly, at this time we can only
speculate about alternative mechanisms by which Cd
could affect the uptake of substrates such as cystatin C.
For example, Herak-Kramberger et al. (1998) have
shown that Cd blocks endocytes in proximal tubule
cells by inhibiting endosomal V-ATPase activity. It is
also possible that some of the changes in the localiza-
tion of molecules such as megalin and cystatin may
occur secondarily to the disruption of cell–cell adhe-
sion and cytoskeletal disruptions that occur during the
early stages of Cd-induced proximal tubule injury (for
review see Prozialeck and Edwards 2012).
The results of the present studies show that the time
course for the Cd-induced increase in urinary cystatin
C excretion occurs at about the same time as the
increase in urinary b2 microglobulin excretion. Since
the increase in the excretion of both proteins probably
results from alterations in proximal tubular reabsorp-
tive function, the obvious question that arises is, does
one marker offer any advantages over the other? In this
regard it is worth noting that while b2 microglobulin is
an early marker of proximal tubule damage, urine
levels can also be altered by pathology and age-related
changes in organs other than the kidney (Bokenkamp
et al. 2001; Prozialeck and Edwards 2010). Cystatin C,
on the other hand, is produced by tissues across the
body at a stable rate regardless of tissue damage and/or
metabolic state (Filler et al. 2005; Sharma et al. 2009)
which potentially makes cystatin C a more reliable
measure of proximal tubule function than b2-
microglobulin.
Another potential benefit of cystatin C as a
biomarker for Cd-induced renal injury is that it is
conserved across species and is an indicator of renal
injury in a variety of species (Ghys et al. 2014). The
availability of another standard marker that is covered
across species could greatly facilitate the extrapolation
of the results of studies in animals to the results of
studies on human populations and vice versa.
One important point to keep in mind with all of the
biomarkers discussed in this report (cystatin C, b2
microglobulin and Kim-1) is that they are very
sensitive, but also general, markers of kidney injury.
Even though they are sensitive markers of injury, none
of the markers are specific indicators of Cd toxicity per
se. Thus, even with the use of these biomarkers to
detect kidney injury, appropriate patient histories and
direct analyses of Cd in tissues and fluids are still
necessary for the appropriate diagnosis of Cd-induced
kidney injury (Prozialeck and Edwards 2010, 2012).
However, the availability of sensitive markers such as
cystatin C may allow for more effective screening and,
perhaps more effective treatment options and clinical
outcomes.
A final aspect of this study that merits attention
involves the relevance of the animal model to the
typical patterns of Cd exposure in humans. All of the
present studies involved the subcutaneous administra-
tion of Cd at doses ranging from 0.6 to 2.4 mg/kg body
weight for up to 12 weeks. This is a standard protocol
that has been widely used by a variety of investigators
in the Cd field including our own initial studies on the
use of Kim-1 as a marker of Cd toxicity (Prozialeck
et al. 2007, 2009a, b; Prozialeck and Edwards 2012).
We would like to emphasize that even though it might
appear that administering Cd by the subcutaneous
route would not mimic the manner in which humans
are typically exposed to Cd (chronic oral ingestion or
inhalation), it actually does. Moreover, this protocol
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offers many advantages for these types of studies. In
utilizing in vivo models to study Cd nephrotoxicity,
investigators must balance the need to be able to do the
studies in a reasonably short time frame with the need
to replicate the toxicokinetics of the long-term, low-
level patterns of exposure that are common in humans
who are typically exposed to dietary or inhaled Cd
over many years or decades. It simply is not possible
or practical to replicate these types of exposure in
species such as rats or mice. Since these species have
shorter life spans, and for many practical reasons,
exposure levels used in animal studies must be higher,
but shorter in duration, than those of humans.
Cd is a classic cumulative nephrotoxicant. With
higher levels of exposure, nephrotoxic effects occur
more quickly than with lower levels of exposure.
There is a direct inverse linear relationship between
the dose of Cd and the time of exposure that causes
onset of proximal tubule injury (i.e. doubling the dose
produces effects in  the time) (Prozialeck et al.
2007). However, higher doses of Cd can cause injury
to organs other than the kidney, particularly the liver
and gonads. One of the most useful approaches for
nephrotoxicity research has involved the subcutaneous
administration of moderate doses of Cd (0.3–1.2 mg/
kg/day) for periods ranging from 3 to 12 weeks. With
this protocol, it is possible to accurately control the
dosing of the animals and to produce the full spectrum
of Cd’s nephrotoxic effects, ranging from mild to
severe. In addition, the patterns of Cd distribution and
toxicity with this model are comparable to those with
chronic oral exposure (for review see Prozialeck and
Edwards 2010). Most importantly, since this protocol
has been used extensively and is widely accepted as a
standard in the Cd field (Aoyagi et al. 2003; Dudley
et al. 1985; Goyer et al. 1989; Shaikh et al. 1999) it
allows for the comparison and interpretation of results
across different studies.
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